COX-2 Advisory Committee Review Will Include New Celebrex Safety Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee will also “explore ways of further evaluation” of the safety of Pfizer’s Bextra and COX-2s approved in Europe, such as Merck’s Arcoxia. FDA also expects discussion of broader NSAID category, at least for “context.”
You may also be interested in...
Office Of New Drugs' Kweder Will Represent FDA At Vioxx Hearing
Office of New Drugs Acting Director Sandra Kweder. MD, will represent FDA at the Senate Finance Committee hearing on the Vioxx withdrawal Nov. 18
Office Of New Drugs' Kweder Will Represent FDA At Vioxx Hearing
Office of New Drugs Acting Director Sandra Kweder. MD, will represent FDA at the Senate Finance Committee hearing on the Vioxx withdrawal Nov. 18
Bextra Meta-Analyses Could Be Taken Up At February COX-2 Advisory Cmte.
Drug safety committee member Curt Furberg's meta-analysis suggests increased risk of cardiovascular events for patients with osteoarthritis and rheumatoid arthritis taking Bextra versus placebo while Pfizer points to a meta-analysis of 8,000 patients that did not show an effect. Furberg disinvited by FDA to participate in committee meeting following public comments.